IPO Watch

City Therapeutics Upsizes and Prices IPO at $18 Mid-Point

RNAi-focused clinical-stage biotech City Therapeutics (CTY) has officially priced its upsized initial public offering at $18.00 per share, hitting the…

Iambic Therapeutics Prices IPO at $16 Mid-Point

Iambic Therapeutics (IAM), a San Diego-based Phase 1 cancer biotechnology company, has priced its initial public offering at $16.00 per…

Biotechs Iambic and City Therapeutics Take Center Stage Amid IPO Buzz

Biotechs Iambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are taking center stage this week as the only two…

City Therapeutics Sets Terms for $175 Million IPO

Cambridge, Massachusetts-based clinical biotech firm City Therapeutics has set terms for its upcoming initial public offering on the NASDAQ under…

TRex Bio Prices IPO at $14 to Raise $116.62 Million

South San Francisco-based biotech firm TRex Bio (TRXB) has priced its initial public offering at $14.00 per share—the low end…